Andreas Hohlbaum is a Ph.D. immunologist with extensive experience in R&D focusing on antibodies and next-generation scaffold proteins. They have designed and directed preclinical development, including non-clinical safety evaluations and translational biomarker strategies in clinical programs. At Sanofi, they currently lead a team of toxicologists to advance global Immunology and Inflammation research projects. Previously, Andreas contributed to various roles in organizations such as Ablynx and Pieris AG, supporting drug development from concept to market authorization.
This person is not in the org chart
This person is not in any teams
This person is not in any offices